Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

Abstract

A decoy receptor for SARS-CoV-2 For severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter human cells, the spike protein on the surface of the virus must bind to the host receptor protein, angiotensin-converting enzyme 2 (ACE2). A soluble version of the receptor is being explored as a therapeutic. Chan et al. used deep mutagenesis to identify ACE2 mutants that bind more tightly to the spike protein and combined mutations to further increase binding affinity (see the Perspective by DeKosky). A promising variant was engineered to be a stable dimer that has a binding affinity for the spike protein; it is comparable with neutralizing antibodies and neutralized both SARS-CoV-2 and SARS-CoV-1 in a cell-based assay. In addition, the similarity to the natural receptor may limit the possibility for viral escape. Science , this issue p. 1261 ; see also p. 1167

Cited by papers we hold 20

• Therapeutic antibodies under development for SARS‐CoV‐2 · 2022
  Not checked
• SARS-CoV-2 Susceptibility and ACE2 Gene Variations Within Diverse Ethnic Backgrounds · 2022
  Not checked
• Comparative genomic analysis reveals varying levels of mammalian adaptation to coronavirus infections. · 2021
  Not checked
• Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2 · 2021
  No notice
• A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants · 2021
  Not checked
• Perspectives and potential approaches for targeting neuropilin 1 in SARS-CoV-2 infection · 2021
  Not checked
• COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus · 2021
  Not checked
• SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets · 2021
  No notice
• Emerging SARS-CoV-2 variants of concern and potential intervention approaches · 2021
  No notice
• Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike · 2021
  No notice
• A novel cell culture system modeling the SARS-CoV-2 life cycle · 2021
  No notice
• DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity · 2021
  No notice
• Human ACE2-Functionalized Gold “Virus-Trap” Nanostructures for Accurate Capture of SARS-CoV-2 and Single-Virus SERS Detection · 2021
  No notice
• Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications · 2021
  No notice
• Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2 · 2021
  No notice
• Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2 · 2021
  No notice
• The flexibility of ACE2 in the context of SARS-CoV-2 infection · 2021
  No notice
• Engineered ACE2 receptor traps potently neutralize SARS-CoV-2 · 2020
  No notice
• ACE2 polymorphisms as potential players in COVID-19 outcome. · 2020
  Not checked
• De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2 · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.